Raphael Dolin, M.D.

Most Relevant to Current Projects

Cohen YZ, Dolin R. Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines 2013 Sep;1(3):99-112. PMCID: PMC3967667.

Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia-Pau M, Weijtens M, Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS; B003-IPCAVD004-HVTN091 Study Group. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 1;164(5):313-22.   PMID: 26833336

Dolin R, Graham BS, Greenberg S, Tacket C, Belshe RB, Midthun K, Clements ML, Gorse G, Horgan B, Atmar R, Karzon D, Bonnez W, Fernie B, Montefiori D, Stablein d, Smith G, Koff W, NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med. 1991;114:119-127.

Goepfert PA, Elizaga ML, Seaton KE, et al.; The HVTN 205 Study Group; the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network. Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis. 2014 Jul 1;210(1):99-110. PMCID: PMC4072895.

Baden L, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobiezczyk ME, Kochar N, Tomaras GD, McElrath J, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R. Timing of Plasmid Cytokine (IL-2/Ig) Administration Impacts HIV-1 Vaccine Immunogenicity in HIV Seronegative Subjects. J Infect Dis 2011 Nov;204(10): 1541-1549. Epub 2011 Sep 21. PMID: 21940420 [PubMed – as supplied by publisher].

Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R. Safety and Immunogenicity of Modified Vaccinia Ankara (ACAM3000): Effect of Dose and Route of Administration. J Infect Dis 2010;201(9):1361-70. PMCID: PMC3016847.

Additional Notable Publications

Keefer MC, Bonnez W, Roberts NJ, Dolin R, Reichman RC. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses to mononuclear leukocytes from HIV-1 gp160 vaccine recipients. J Infect Dis. 1991; 163:448-453.

Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, NIAID AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 HIV-1 virus in subjects at low risk of infection. J Infect Dis. 1993;168:1387-1395.

Belshe RB, Graham BS, Keefer MC, Gorse GH, Wright P, Dolin R, Matthews TJ, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twadell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast P (NIAID AIDS Vaccine Clinical Trials Network). Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA. 1994;272:475-480.

Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, and the AIDS Vaccine Clinical Trials Network. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res and Human Retroviruses. 1994;10:1713-1723.

Graham B, Gorse G, Schwartz D, Keefer M, McElrath MJ, Matthews T, Wright P, Belshe R, Clements ML, Dolin R, Corey L, Bolognesi DP, Stablein DM, Esterlitz JR, Hu SL, Smith GE, NIAID AIDS Vaccine Clinical Trials Network. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naïve volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis. 1994; 170:782-786.

Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh R-H, Chernoff D, Dekker C, Dolin R. Safety and immunogenicity of env 2-3, a human immunodeficiency virus type-1 candidate vaccine in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses, 1996;12:683-693.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng’ang’a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilrag A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin, R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. International seroepidemiology of adenovirus serotyped 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, doi:10.1016/j.vaccine.2011.05.025. PMCID: PMC3138857 [Available on 2012/7/18].

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;6(8): e21225. Epub 2011 Aug 3. PMCID: PMC3152265.

McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P, AIDS Vaccine Evaluation Group. A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection. AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):907-19.

Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R. Effect of Immunization with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax. J Infect Dis 2010;201(9):1353-60. PMCID: PMC3023456.

Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 June;207(12):1888-97. Epub 2013 Mar. 12. PMCID: PMC3654753.